NHS Rolls Out One-Minute Cancer Injection to Tens of Thousands of Patients

Level 3 — Intermediate

On Monday, May 11, 2026, the UK's National Health Service began rolling out a subcutaneous formulation of pembrolizumab — sold under the brand name Keytruda — to cancer patients in England and Wales. Hospitals across the rest of the UK can now place orders for the new version following approval by the country's medicines regulator.

Pembrolizumab is a checkpoint-inhibitor immunotherapy. It works by blocking a protein called PD-1 on immune cells, freeing those cells to recognize and attack cancerous tumors. It is already used in the UK for 14 different cancer types, including non-small-cell lung cancer, melanoma, breast cancer, head-and-neck cancer, and several forms of cervical cancer.

Until now, the drug was delivered as an intravenous drip that could take up to two hours per session, tying up a chemotherapy chair and a nurse for much of that time. The new subcutaneous injection is given in the upper thigh or abdomen and delivers the same dose in roughly 60 seconds, every three or six weeks depending on the cancer type.

NHS England estimates that around 14,000 patients each year will benefit from the change, with an expected saving of tens of thousands of hours of clinical time. Clinical trial data published in 2025 showed the injection produced the same drug levels in the blood and similar safety as the intravenous form, paving the way for regulatory approval and the current rollout.

subcutaneous: Beneath the skin.

formulation: A particular way a medicine is prepared, such as a tablet or injection.

checkpoint inhibitor: A drug that blocks a protein that normally stops immune cells from attacking other cells.

tumor: A lump or growth of abnormal cells in the body.

intravenous: Given directly into a vein.

dose: A measured amount of medicine taken at one time.

regulator: An official body that approves and controls products such as medicines.

clinical trial: A scientific study that tests how well a treatment works in patients.

Level 4 — Advanced

On Monday, May 11, 2026, NHS England launched the rollout of a subcutaneous formulation of pembrolizumab — the world's best-selling oncology drug, marketed by Merck & Co. as Keytruda — to patients in England and Wales, with NHS trusts in Scotland and Northern Ireland now eligible to order the product. The shift follows last month's marketing authorization by the UK's Medicines and Healthcare products Regulatory Agency on the basis of the Phase III KEYNOTE-D77 non-small-cell lung cancer trial, which demonstrated bioequivalence to intravenous pembrolizumab and a non-inferior safety profile.

Pembrolizumab is the archetypal anti-PD-1 checkpoint inhibitor. By binding the programmed-cell-death-1 receptor expressed on activated T cells, the antibody prevents tumor cells from co-opting the PD-1/PD-L1 axis to evade immune surveillance. The drug has accumulated more than 20 NICE-recommended UK indications since its 2015 launch, spanning non-small-cell lung, melanoma, triple-negative breast, head-and-neck squamous cell, cervical, renal-cell, urothelial, gastric and microsatellite-instability-high tumors across diverse lines of therapy.

Clinically, the operational implications are substantial. The intravenous regimen requires roughly a two-hour chair time per cycle when factoring in pharmacy preparation, line flushing and observation; the subcutaneous version, packaged with a recombinant hyaluronidase to allow rapid drug dispersion through interstitial tissue, can be delivered in approximately 60 seconds every three weeks or 120 seconds every six weeks. NHS modelling, replicated by independent NICE costing analysts, estimates a freeing of at least 100,000 outpatient chair-hours per year nationally and the redirection of nursing capacity toward additional drug administration and supportive care.

The rollout also sets a precedent for the broader subcutaneous reformulation movement among monoclonal-antibody therapeutics. Roche's atezolizumab, BMS's nivolumab and Regeneron's cemiplimab — all checkpoint inhibitors with overlapping indications — have either launched or are in late-stage regulatory review for their own under-the-skin versions. Health economists view this trend as a key lever for absorbing the rising incidence of cancer in aging populations without proportional growth in oncology infrastructure, although questions remain about home-administration safety, autoinjector ergonomics for elderly patients, and equity of access between teaching hospitals and rural trusts.

bioequivalence: When two formulations of the same drug produce equivalent concentrations in the blood and equivalent effects in the body.

non-inferior: Statistically shown not to be meaningfully worse than a comparator treatment.

checkpoint inhibitor: A drug that blocks a protein that normally restrains immune cells, allowing them to attack tumor cells.

immune surveillance: The body's ongoing process of detecting and destroying abnormal cells before they form tumors.

indication: A specific disease or condition for which a drug is officially approved.

hyaluronidase: An enzyme that breaks down hyaluronic acid in tissue, allowing fluids and drugs to spread more easily under the skin.

monoclonal antibody: A laboratory-made protein designed to bind to a single specific target on a cell.

outpatient: A patient who receives treatment without being admitted to a hospital bed overnight.

Level 1 — Absolute Beginner

Level 2 — Elementary

Level 3 — Intermediate

Level 4 — Advanced

NHS Rolls Out One-Minute Cancer Injection to Tens of Thousands of Patients

Multiple Choice

True or False

Fill in the Blank